Marinus Verwijs - 02 Nov 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
SENIOR VICE PRESIDENT, CMC
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
02 Nov 2022
Net transactions value
-$21,346
Form type
4
Filing time
03 Nov 2022, 17:00:10 UTC
Previous filing
23 Mar 2022
Next filing
08 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Sale $21,346 -1,130 -100% $18.89 0 02 Nov 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022.
F2 Includes 1,130 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).